Safety and Efficacy of Rituximab in Multiple Sclerosis: A Retrospective Observational Study.
Conclusion: In our real-world cohort, rituximab was well-tolerated and effective in reducing relapse rate and disability progression in relapsing-remitting and progressive MS patients.
PMID: 30539030 [PubMed - in process]
Source: Journal of Immunology Research - Category: Allergy & Immunology Tags: J Immunol Res Source Type: research
More News: Allergy & Immunology | Disability | Lebanon Health | Men | Middle East Health | MRI Scan | Multiple Sclerosis | Rituxan | Study